Monthly summaries of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Aerpio Pharmaceuticals, Inc.
since 2005 are illustrated in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Aerpio Pharmaceuticals, Inc. since year 2005.
Table 2 shows the detailed insider transactions of Aerpio Pharmaceuticals, Inc. since 2005.
The reporting company's ticker symbol is ARPO. The reporting company's CIK number is 1422142.
The total value of stock buying since 2005 is $33,420,629.
The total value of stock sales since 2005 is $20,670.
The total value of stock option exercises since 2005 is $0.
|Trading Period||Insider Buying||Insider Sales||Option Exercises|
|Trade Date||Insider Name||Trade Type||Shares||Price ($)||Value ($)|
|2018-12-11||Satter Muneer A (Director)||Buy||20,000||2.09||41,840|
|2018-12-10||Satter Muneer A (Director)||Buy||20,000||2.13||42,600|
|2018-12-07||Satter Muneer A (Director)||Buy||20,000||2.14||42,779|
|2018-12-06||Satter Muneer A (Director)||Buy||20,000||2.18||43,580|
|2018-12-04||Satter Muneer A (Director)||Buy||20,000||2.10||42,000|
|2018-12-03||Satter Muneer A (Director)||Buy||20,000||1.99||39,780|
|2018-11-30||Satter Muneer A (Director)||Buy||20,000||1.99||39,700|
|2018-11-29||Satter Muneer A (Director)||Buy||20,000||2.01||40,119|
|2018-11-28||Satter Muneer A (Director)||Buy||20,000||1.94||38,720|
|2018-11-12||Hoffman Stephen J (Chief Executive Officer)||Buy||30,000||2.01||60,299|
|2018-11-09||Hoffman Stephen J (Chief Executive Officer)||Buy||1,967||1.95||3,835|
|2018-08-20||Novartis Ag (10% Owner)||Sale||5,300||3.90||20,670|
|2018-06-28||Orbimed Capital Gp V Llc||Buy||777,500||3.85||2,993,375|
|2018-06-28||Khuong Chau Quang||Buy||777,500||3.85||2,993,375|
|2018-06-28||Satter Muneer A (Director)||Buy||1,818,182||3.85||7,000,000|
|2018-03-23||Satter Muneer A (Director)||Buy||1,000||5.00||5,000|
|2018-03-21||Satter Muneer A (Director)||Buy||4,000||4.85||19,392|
|2018-03-20||Satter Muneer A (Director)||Buy||5,400||4.97||26,859|
|2018-03-19||Satter Muneer A (Director)||Buy||7,600||4.96||37,726|
|2017-03-15||Gardner Joseph H. (See Remarks)||Buy||99,996||5.00||499,980|
|2017-03-15||Peters Kevin G. (Chief Scientific Officer)||Buy||3,642||5.00||18,210|
|2017-03-15||Khuong Chau Quang (Director)||Buy||762,995||5.00||3,814,975|
|2017-03-15||Castelein Caley (Director)||Buy||400,000||5.00||2,000,000|
|2017-03-15||Satter Muneer A (Director)||Buy||1,120,000||5.00||5,600,000|
|2017-03-15||Weiss Paul M (Director)||Buy||272,302||5.00||1,361,510|
|2017-03-15||Novartis Ag (10% Owner)||Buy||560,000||5.00||2,800,000|
|2017-03-15||Isaly Samuel D (Director)||Buy||762,995||5.00||3,814,975|
Insider trading activities including stock purchases, stock sales, and option exercises of ARPO listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Aerpio Pharmaceuticals, Inc. (symbol ARPO, CIK number 1422142) see the Securities and Exchange Commission (SEC) website.